Tartu-based Better Medicine, a startup creating AI-powered diagnostic instruments for radiology, has raised €1 million in a pre-Seed funding spherical to develop in Europe, put together for U.S. entry, and pursue scientific and insurance coverage partnerships.
The spherical was led by Soulmates Ventures, with participation from Specialist VC, UT Ventures, and a number of other angel buyers. The spherical gained momentum after a €2.5 million grant awarded by the European Innovation Council (EIC) originally of 2024. In complete, with further grants, Higher Medication has now secured €2.25 million in personal funding and €3.7 million in complete grants, bringing its total funding to almost €6 million.
“Radiologists are underneath immense strain to keep up complete concentrate on extremely repetitive duties that don’t essentially require medical experience however are nonetheless essential for analysis,” stated Priit Salumaa, Founder and CEO of Higher Medication. “Think about a second set of eyes, however multiplied by 1000, all the time alert and by no means drained: we’re making early most cancers detection simple and liberating medical doctors to keep away from burnout and concentrate on what actually requires their judgment. The upside is extra human lives saved.”
Based in 2020, Higher Medication operates with a worldwide crew throughout six international locations, bringing experience in medical apply and analysis, laptop science, and startup improvement. The corporate has secured scientific collaborations with companions together with Leeds Educating Hospitals NHS Belief, Tartu College Hospital, Tartu College, and Pärnu Hospital, amongst others.
Its BMVision platform integrates instantly into radiologists’ workflows to detect and measure oncological findings, beginning with kidney lesions.
Radiology departments worldwide face mounting strain from a rising quantity of scans and a scarcity of certified professionals. Within the UK, there are simply 10 radiologists per 100,000 people, and a latest survey stories that 50% of radiology job postings go unfilled. Demand for imaging is anticipated to grow with an aging population, outpacing the expansion in medical doctors.
This imbalance contributes to delays, missed diagnoses, and burnout. Globally, an estimated 12 million hours per yr are spent on handbook lesion measurements and reporting.
Higher Medication seems to be to deal with this problem by deploying clinically validated AI fashions that help radiologists with detection, measurement, and reporting of oncological findings in CT scans. The expertise permits automated lesion detection and measurement whereas integrating into commonplace radiology infrastructure, together with PACS and viewers.
The corporate’s flagship product, BMVision Kidney, lately obtained CE certification as a Class IIa medical gadget underneath the EU Medical Gadget Regulation (MDR 2017/745), making it the primary CE-certified, AI-based kidney most cancers detection software compliant with the regulation.
In scientific evaluations, radiologists utilizing BMVision have reported as much as 52% time financial savings and a 99.2% detection price.
BMVision Kidney makes use of deep-learning fashions educated on annotated scientific datasets to detect malignant kidney lesions. In scientific research, the answer achieved 96% standalone accuracy and 99.2% detection price when mixed with radiologist evaluation.
A companion software, BM iMeasure, permits semi-automated lesion measurements and structured reporting.
“Higher Medication is addressing a transparent and pressing want in oncology diagnostics,” stated Michal Sikyta, Funding Director at Soulmates Ventures. “By supporting radiologists and different specialists with dependable AI instruments, they’re serving to enhance affected person outcomes whereas easing strain on overloaded well being programs. We’re excited to again an skilled crew as they put together to make a serious influence in trendy medication.”
The brand new funding will assist Higher Medication’s business rollout throughout a number of European international locations, enlargement of its product portfolio to cowl further organs and metastatic websites, and preparation for FDA clearance.
The corporate plans to launch scientific pilots within the U.S. tailor-made to FDA research necessities and is partaking with medical health insurance suppliers in Estonia to display cost-benefit outcomes as a pathway to sustainable market adoption.
